Assessment of effect modification of statins on new-onset diabetes based on various medical backgrounds: a retrospective cohort study

Keiko Yamazaki 1, Yasuo Takahashi 1*, Kotoe Teduka 1, Tomohiro Nakayama 2, Yayoi Nishida 3 and Satoshi Asai 3

Abstract

**Background:** The aim of this study was to investigate the association between statin use and new-onset diabetes in clinical settings and to assess its effect modification (heterogeneity) among patients with various medical histories and current medications.

**Methods:** In a total of 12,177 Japanese patients without diabetes, from December 2004 to November 2012, we identified 500 statin users and 500 matched non-users using propensity-score matching. Patients were followed until December 2017. We estimated the hazard ratios of new-onset diabetes associated with statin use. We also tested the heterogeneity of the treatment effect by evaluating subgroup interactions in subgroups according to sex, age, medical history, and current medication.

**Results:** New-onset diabetes had occurred in 71 patients (13.6%) with statin use and 43 patients (8.3%) with non-use at 5 years (hazard ratio, 1.66; 95% confidence interval [CI], 1.11 to 2.48; \( P = 0.0143 \)), and in 78 patients (15.6%) with statin use and 48 patients (9.6%) with non-use at 10 years (hazard ratio, 1.61; 95% CI, 1.10 to 2.37; \( P = 0.0141 \)). There were no significant treatment-by-subgroup interactions in all subgroups defined according to sex, age, medical history, and current medication.

**Conclusions:** In patients with various clinical backgrounds, those who received statin therapy had a higher risk of new-onset diabetes at 5 and 10 years than those who did not receive it. Effect modification of statins on new-onset diabetes was not found in patient populations defined according to various comorbid diseases or concomitant drugs.

**Keywords:** Retrospective cohort study, Clinical database, New-onset diabetes mellitus, Statin, Propensity-score matching

Background

The use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, known as statins, can effectively reduce cardiovascular events and mortality [1, 2]. Current guidelines, such as the National Institute for Health and Clinical Excellence (NICE) guidelines [3] and the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines [4], recommend statins for primary and secondary prevention of cardiovascular disease as assessed with a recommended risk score. Although statins are generally considered to be safe and well tolerated [5], there is concern about the relation between the use of statins and the development of diabetes mellitus [6–9]. Randomized controlled trials and meta-analyses have reported unfavorable results that statin therapy is associated with an increased incidence of new-onset diabetes [10–13]. The effect of statins on the development of diabetes appears to be dose-dependent and differentiated between different types of
statins [14–18], and to be associated with adherence and duration of therapy [15, 19]. Recent observational studies reported that increased incidence of new-onset diabetes with statin use has also been seen in particular patient populations, including women, healthy adults, and East Asian people [20–24].

In clinical practice, all complications and comorbid conditions, i.e., the clinical characteristics, as well as cardiovascular risk factors, should be assessed before starting statin therapy, although comorbid conditions, including hypertension, obesity, and diabetes mellitus, which are commonly observed in patients with dyslipidemia, are major risk factors for cardiovascular disease. Therefore, whether the effect of statins on glycemic control may vary in particular patient populations defined according to various comorbid diseases or concomitant drugs, such as cardiovascular disease, hypertension and medications for these conditions, would be of interest. There is, however, a paucity of reports providing data from a comprehensive analysis of medical history and current medication, which may modify the effect of statins on new-onset diabetes.

The aim of the present study was to examine whether statin therapy could increase the risk of new-onset diabetes among patients with various backgrounds in clinical settings and to assess its effect modification (heterogeneity) in various subgroups defined by sex, age, medical history, and current medication, using a clinical database in Japan.

Methods

Data source

We obtained the study data from December 1, 2004 to December 31, 2017 using the Nihon University School of Medicine (NUSM) Clinical Data Warehouse (CDW), which is a centralized data repository that integrates separate databases, including an order entry database and a laboratory results database, from the electronic medical record system at three hospitals affiliated with NUSM, and is described elsewhere [25]. The prescription database in the CDW contains information from approximately 0.8 million patients, and prescribing data are linked longitudinally to detailed clinical information such as patient demographics, diagnosis, and laboratory data. To protect patient privacy, patient identifiers are replaced with anonymous identifiers in all databases of this CDW. Several epidemiological studies in various therapeutic areas using NUSM’s CDW have been published [26–33].

The experimental protocol was approved by the Ethical Committee of Nihon University School of Medicine, and the study was conducted in compliance with the Helsinki Declaration and the Ethical Guidelines for Medical and Health Research Involving Human Subjects of the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare, Japan. No informed consent was required because this was a retrospective observational study using anonymized archived data from a clinical database and did not compromise anonymity or confidentiality.

Study design and population

This was a retrospective cohort study evaluating the effects of statin versus no statin treatment on new-onset diabetes in patients with different medical histories. The study was divided into two periods: 1) an entry period (December 1, 2004 to November 30, 2012), which was used for selection of study subjects and description of baseline characteristics; and 2) a follow-up period (from the index date as defined below until December 31, 2017), which was used to capture outcome events.

The cohorts identified for the study included Japanese patients at Nihon University Itabashi Hospital aged 30 to 85 years, and who met the following criteria:

1. At least one outpatient visit to undergo laboratory tests, including plasma glucose or hemoglobin A1c (HbA1c), during both the entry and follow-up periods

We identified treatment groups who fulfilled the following criteria:

1. Statin users: patients who had been newly treated with a statin for at least 90 days during the entry period as described previously [22, 24]. The index date was defined as the date of the first prescription of a statin. We excluded patients who received a statin for less than 90 days or who had been newly treated with a statin after December 1, 2012 (outside the entry period).

2. Statin non-users: patients who did not receive a statin during the study period (entry and follow-up periods), and were followed up for at least 90 days after the index date, which was defined as the earliest date of a blood test for either plasma glucose or HbA1c during the entry period

We excluded patients who met the following criteria:

1. Patients who had schizophrenia or renal failure, or who had been treated with immunosuppressive drugs or steroids during the study period.

2. Patients with a diagnosis of diabetes or prescribed medication for diabetes prior to the index date.

3. Patients with missing values of serum triglyceride data during the 90 days preceding the index date.
4. Patients who fulfilled the following criteria for test results prior to the index date: either elevated casual plasma glucose level ≥ 126 mg/dl, or locally measured 2 h glucose ≥ 200 mg/dl following a 75 mg oral glucose tolerance test (OGTT) or elevated HbA1c ≥ 6.5%.

Consequently, we identified 519 new users of statins and 11,658 statin non-users who fulfilled the above criteria (Fig. 1). Then, we identified an equal number of statin users (N = 500) and matched non-users (N = 500) after propensity-score matching, and compared them.

**Outcome**

We defined our diabetes endpoints as follows:

1. Clinical diagnosis of diabetes in combination with at least one blood test result as follows: either elevated casual plasma glucose level ≥ 200 mg/dl or locally measured 2 h glucose ≥ 200 mg/dl following a 75 mg OGTT or elevated HbA1c ≥ 6.5%, according to the Committee for the Classification and Diagnosis of Diabetes Mellitus of the Japan Diabetes Society [34].

2. Initiation of insulin or an oral hypoglycemic drug

Patients were followed from 91 days after the index date until the diabetes endpoint occurred, or were assessed up to the final visit (censored). We created two datasets of 5-year and 10-year follow-up data to perform long-term analysis at different time points.

---

**Fig. 1** Identification of study population

Cohorts of statin users and non-users were matched using propensity-score matching after a screening procedure (i.e., some patients were excluded for the reasons shown in the figure).
Covariates
For each individual, information on patient demographics (age and sex), medical history, current medication, and laboratory results was collected. Medical history included information on cerebrovascular disease (ICD-10 codes, I60-I69), ischemic heart disease (I20-I25), other heart disease (I30-I52), liver disease (K70-K77), kidney disease (N00-N19), rheumatoid arthritis (M5, M6), and hypertension (I10) that had been diagnosed prior to the index date. We recorded current users of medication including antihypertensive agents (including angiotensin receptor blockers (ARB), angiotensin converting enzyme (ACE) inhibitors, β-blockers, calcium channel blockers (CCB), antihypertensive diuretics and other antihypertensive drugs), lipid-lowering drugs (including fibrates, bile acid sequestrants, nicotinic acid, cholesterol absorption inhibitors and other lipid-lowering drugs), antithrombotic drugs, liver disease therapeutics, kidney disease therapeutics, non-steroidal anti-inflammatory drugs (NSAID), proton pump inhibitors (PPI), histamine2-receptor antagonists (H2 blockers), non-thiazide diuretics and anti-arrhythmic drugs, defined as patients who had received these agents in the 90 days preceding the index date.

Also, blood test data (triglyceride and casual plasma glucose) were collected for each individual during the 90 days preceding the index date.

Propensity-score matching
Because this study was an observational study, which involves inherent issues of selection bias, we used propensity score matching (greedy 1:1 matching) to reduce bias by balancing covariates between statin users and non-users. This method is an effective tool to reduce bias in nonrandomized studies [35, 36], and is described elsewhere [37]. In brief, the propensity score for each subject was obtained by fitting a logistic regression model that included the predictor variable as an outcome and baseline covariates including follow-up period, age, sex, medical history, current medication, and baseline levels of triglyceride and casual glucose. All covariates were included in the model. Hazard ratio in all analyses was adjusted for age and baseline levels of triglyceride and casual glucose. All reported P values are two-sided, and an alpha level of 0.05 was considered to indicate statistical significance. All statistical analyses were performed with SAS software, version 9.3 (SAS Institute Inc., Cary, NC).

Results
Study subjects
Based on our initial inclusion and exclusion criteria, we identified a total of 12,177 patients for this study; 519 statin users and 11,658 non-users. After propensity-score matching, the study included 500 statin users and 500 matched non-users (Fig. 1). The mean follow-up in all subjects was 150.4 weeks; the length (mean ± standard error) of follow-up was likely to be longer in statin non-users (152.6 ± 6.4 weeks) than in statin users (148.3 ± 6.4 weeks), but the difference between them was not significant. During the follow-up period, 121 patients were exposed to atorvastatin, 24 to fluvastatin, 70 to pitavastatin, 71 to pravastatin, 110 to rosuvastatin, 18 to simvastatin, and 86 to two or more types of statins. Table 1 shows the baseline characteristics of the patients after propensity-score matching. In statin users, mean age was 60.0 years and 56.2% were women. Statin non-users were older, but showed a similar proportion of women to statin users; mean age was 61.2 years and 57.8% were women. There were no significant differences in medical history and current medication between statin users and non-users. Approximately half of each cohort had a history of hypertension, and one-fifth had a history of ischemic heart disease or other heart disease. More than two-fifths of each cohort took an antihypertensive drug, approximately one-third took an antithrombotic drug, and approximately one-fourth took an NSAID. In laboratory parameters, there was no significant difference in triglyceride and casual glucose levels between statin users and non-users.

Risk of new-onset diabetes
New-onset diabetes had occurred in 71 patients (13.6%) with statin use and 43 patients (8.3%) with non-use at 5 years (adjusted hazard ratio, 1.66; 95% confidence interval [CI], 1.12 to 2.48; P = 0.0143) (Table 2). At 10 years, new-
Table 1 Baseline characteristics of study population after propensity-score matching

| Characteristics                  | Statin users | Statin non-users | P value |
|----------------------------------|--------------|------------------|---------|
| **Age (years, mean ± sd)**       |              |                  |         |
| Women                            | 60.0 ± 10.9  | 61.2 ± 13.8      | 0.1241  |
| Medical history                  |              |                  |         |
| Cerebrovascular disease          | 75 (15.0)    | 76 (15.2)        | 0.9296  |
| Ischemic heart disease           | 115 (23.0)   | 102 (20.4)       | 0.3186  |
| Other heart disease              | 112 (22.4)   | 101 (20.2)       | 0.3955  |
| Rheumatoid arthritis             | 15 (3.0)     | 18 (3.6)         | 0.5954  |
| Liver disease                    | 68 (13.6)    | 68 (13.6)        | 1.0000  |
| Kidney disease                   | 20 (4.0)     | 25 (5.0)         | 0.4456  |
| Hypertension                     | 103 (20.6)   | 82 (16.4)        | 0.0872  |
| Medication                       |              |                  |         |
| Antihypertensive drugs           | 216 (43.2)   | 194 (38.8)       | 0.1572  |
| ARB                              | 110 (22.0)   | 112 (22.4)       | 0.8790  |
| ACEI                             | 19 (3.8)     | 20 (4.0)         | 0.8702  |
| Beta blocker                     | 35 (7.0)     | 33 (6.6)         | 0.8016  |
| CCB                              | 124 (24.8)   | 120 (24.0)       | 0.7684  |
| Antihypertensive diuretic        | 4 (0.8)      | 5 (0.9)          | 0.1428  |
| Other antihypertensive drugs     | 57 (11.4)    | 57 (11.4)        | 1.0000  |
| Lipid-lowering drugs other than statins |          |                  |         |
| Fibrate                          | 13 (2.6)     | 15 (3.0)         | 0.7014  |
| Bile acid sequestrant            | 4 (0.8)      | 4 (0.8)          | 1.0000  |
| Nicotinic acid                   | 7 (1.4)      | 5 (1.0)          | 0.5613  |
| Cholesterol absorption inhibitor | 1 (0.2)      | 0 (0.0)          | 0.3171  |
| Other lipid-lowering drugs       | 16 (3.2)     | 13 (2.6)         | 0.5718  |
| Antithrombotic drug              | 182 (36.4)   | 193 (38.6)       | 0.4724  |
| Liver disease therapeutic        | 11 (2.2)     | 9 (1.8)          | 0.6514  |
| Kidney disease therapeutic       | 4 (0.8)      | 6 (1.2)          | 0.5250  |
| Proton pump inhibitor            | 92 (18.4)    | 79 (15.8)        | 0.2749  |
| H2 blocker                       | 60 (12.0)    | 70 (14.0)        | 0.3471  |
| NSAID                            | 129 (25.8)   | 131 (26.2)       | 0.8854  |
| Non-thiazide diuretic            | 35 (7.0)     | 34 (6.8)         | 0.9007  |
| Antiarhythmic drug               | 45 (9.0)     | 46 (9.2)         | 0.9124  |
| Laboratory parameters            |              |                  |         |
| Triglyceride (mg/dL, mean ± sd)  | 134.7 ± 65.4 | 134.4 ± 75.8     | 0.8494  |
| Casual glucose (mg/dL, mean ± sd) | 102.2 ± 10.0 | 101.8 ± 10.6     | 0.6250  |

Data are numbers of individuals (%) unless otherwise stated. Comparisons of differences in patient characteristics between groups were performed using t-test for continuous variables and chi-squared test for categorical data.

Abbreviations: ARB Angiotensin II receptor blocker, CCB Calcium channel blocker, ACEI Angiotensin-converting enzyme inhibitor, H2 Blocker, histamine2-receptor antagonist, NSAID Non-steroidal anti-inflammatory drug.
the following limitations paragraph). Our study was an observational study using non-randomized data and included patients with various backgrounds and clinical settings, who had comorbid conditions and were treated in our hospital. Therefore, the possibility that these would influence the results of this study cannot be ruled out. Furthermore, our finding that the hazard ratios of statin use for new-onset diabetes at 5 and 10 years were similar suggests a possible long-term effect of statin use on the development of new-onset diabetes mellitus.

Regarding the effect modification of statins on new-onset diabetes, we could not demonstrate any significant treatment-by-subgroup interaction in subgroups defined according to sex, age group, medical history, and current medication. There is a possibility that the statistical power may have been insufficient for assessing the interaction in some subgroups with a small sample size. However, this study showed that the hazard ratio of statin use for new-onset diabetes was higher in the subgroup with a history of ischemic heart disease than in the subgroup without, although the interaction between statin use and a history of ischemic heart disease was not significant. These results may suggest the potential increased risk of statin use for new-onset diabetes in patients with a history of ischemic heart disease. The underlying mechanism of these links between statin effect and history of ischemic heart disease responsible for the development of diabetes is not clear. The strongest predictors of new-onset diabetes include older age, higher blood glucose level, and features of the metabolic syndrome, such as obesity and raised triglycerides [6, 40]. These conditions are partially in common with risk factors for heart disorders, including coronary heart disease. Therefore, there is a possibility that statins may unmask diabetes, via which statins and these heart diseases themselves interact together, in people with a history of ischemic heart disease, who are more likely to develop diabetes. Our findings provide important clinical information to explain the diabetes risk in patients starting statin therapy, especially in those with a history of these heart diseases, although the benefit of statins to decrease cardiovascular risk completely outweighs the diabetes risk [18]. It is well-known that the reliability of subgroup analysis is likely to be reduced because of a combination of reduced statistical power and increased variance [40]. Therefore, the possibility that our findings of subgroup analysis may derive from the play of chance should be considered. Further studies with large samples will be needed to assess the effect

![Kaplan–Meier plot of new-onset diabetes-free survival in statin users and non-users](image)

**Fig. 2** Kaplan–Meier plot of new-onset diabetes-free survival in statin users and non-users. Kaplan–Meier survival curves showed a significantly higher occurrence rate of new-onset diabetes in the statin user group than in the matched non-user group ($P < 0.001$, log-rank test). Tick marks indicate censored data.

| Outcome                  | Statin users (N = 500) | Statin non-users (N = 500) | Unadjusted | Adjusted* |
|-------------------------|------------------------|-----------------------------|------------|-----------|
|                         | No. of events (%)      |                             | HR (95% CI) | P value   |
| New-onset diabetes at 5 years | 71 (13.6)             | 43 (8.3)                    | 1.74 (1.20–2.55) | 0.0039    |
| New-onset diabetes at 10 years | 78 (15.6)            | 48 (9.6)                    | 1.69 (1.19–2.44) | 0.0040    |

*Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox hazards models adjusted for age, and baseline levels of triglyceride and casual blood glucose
| Subgroup                     | No. of patients | Statin users | Non-users | Hazard ratio | P value for interaction |
|-----------------------------|-----------------|--------------|-----------|--------------|--------------------------|
|                             | No. of events (%) |               |           | (95% CI)     |                          |
| All patients                | 1000            | 78 (15.6)    | 48 (9.6)  | 1.61 (1.10–2.37) |                          |
| Age                         |                 |              |           |              |                          |
| < 65 yr                     | 596             | 46 (14.1)    | 22 (8.2)  | 1.52 (0.90–2.58) | 0.8219                   |
| ≥ 65 yr                     | 404             | 32 (18.4)    | 26 (11.3) | 1.67 (0.93–2.99) |                          |
| Sex                         |                 |              |           |              |                          |
| Female                      | 581             | 39 (13.7)    | 25 (8.4)  | 1.66 (0.94–2.92) | 0.9035                   |
| Male                        | 431             | 38 (17.1)    | 22 (10.5) | 1.58 (0.94–2.66) |                          |
| Medical history             |                 |              |           |              |                          |
| Cerebrovascular disease     |                 |              |           |              |                          |
| Yes                         | 151             | 13 (17.3)    | 9 (11.8)  | 1.00 (0.37–2.66) | 0.2935                   |
| No                          | 849             | 65 (15.3)    | 39 (9.2)  | 1.77 (1.17–2.70) |                          |
| Ischemic heart disease      |                 |              |           |              |                          |
| Yes                         | 217             | 29 (25.2)    | 12 (11.8) | 2.28 (1.11–4.66) | 0.2279                   |
| No                          | 783             | 49 (12.7)    | 36 (9.1)  | 1.34 (0.84–2.14) |                          |
| Other heart disease         |                 |              |           |              |                          |
| Yes                         | 213             | 25 (22.3)    | 12 (11.9) | 1.59 (0.78–3.24) | 0.9372                   |
| No                          | 787             | 53 (13.7)    | 36 (9.0)  | 1.54 (0.97–2.44) |                          |
| Liver disease               |                 |              |           |              |                          |
| Yes                         | 136             | 4 (5.9)      | 6 (8.8)   | 1.45 (0.65–3.27) | 0.7781                   |
| No                          | 864             | 74 (9.7)     | 42 (9.7)  | 1.65 (1.10–2.44) |                          |
| Hypertension                |                 |              |           |              |                          |
| Yes                         | 450             | 44 (18.9)    | 26 (12.0) | 1.57 (0.87–2.81) | 0.9993                   |
| No                          | 550             | 34 (12.7)    | 22 (7.8)  | 1.57 (0.87–2.64) |                          |
| Medication                  |                 |              |           |              |                          |
| ARB use                     |                 |              |           |              |                          |
| Yes                         | 410             | 39 (18.1)    | 22 (11.3) | 1.31 (0.78–2.21) | 0.2802                   |
| No                          | 590             | 39 (13.7)    | 26 (8.5)  | 1.87 (1.16–3.01) |                          |
| CCB use                     |                 |              |           |              |                          |
| Yes                         | 222             | 25 (22.7)    | 13 (11.6) | 1.31 (0.70–2.46) | 0.4316                   |
| No                          | 778             | 53 (13.6)    | 35 (9.0)  | 1.72 (1.13–2.63) |                          |
| Beta blocker use            |                 |              |           |              |                          |
| Yes                         | 244             | 23 (18.6)    | 12 (10.0) | 1.61 (0.84–3.08) | 0.9948                   |
| No                          | 756             | 55 (14.6)    | 36 (9.5)  | 1.62 (1.06–2.47) |                          |
| Other antihypertensive drug use |             |              |           |              |                          |
| Yes                         | 68              | 8 (22.9)     | 5 (15.2)  | 0.84 (0.33–2.12) | 0.1378                   |
| No                          | 932             | 70 (15.1)    | 43 (9.2)  | 1.71 (1.15–2.54) |                          |
| Antithrombotic drug use     |                 |              |           |              |                          |
| Yes                         | 114             | 11 (19.3)    | 9 (15.8)  | 1.15 (0.41–3.20) | 0.4685                   |
| No                          | 886             | 67 (15.1)    | 39 (8.8)  | 1.73 (1.14–2.63) |                          |
| Proton pump inhibitor use   |                 |              |           |              |                          |
| Yes                         | 375             | 36 (19.8)    | 26 (13.5) | 1.40 (0.80–2.43) | 0.5513                   |
| No                          | 625             | 42 (13.2)    | 22 (7.2)  | 1.89 (1.09–3.27) |                          |
modification of statin therapy on new-onset diabetes in patients with various backgrounds.

Our study has several limitations. It was a retrospective observational study with non-randomized data, which has some issues with respect to the potential for selection bias. We used rigorous statistical methods to balance potential confounding variables between statin users and non-users, including a propensity-score matching method. However, their ability to control for differences was limited to variables that were available or measurable. In this study, information on some biographical characteristics including smoking, alcohol consumption and family history of diabetes was not available, and we could not account for them. In addition, the model used in this study was not adjusted for body mass index (BMI) because of a large number of missing data of BMI in the study population. The possibility that this may have impacted on our results cannot be excluded, because individuals with higher BMI are more likely to develop new-onset diabetes [8]. However, BMI is well known to be closely related to serum triglyceride level. We, therefore, included baseline triglyceride level as a covariate for adjustment, minimizing the effect of unavailability of BMI. We also included age and baseline casual glucose level for adjustment, in addition to triglyceride level, because they are the strongest predictors of new-onset diabetes [6, 41].

Second, the dose of statins was not controlled and the type of statins was not assessed, because the population was small. However, the comparative effects of treatment with various statins, such as high potency vs low potency, lipophilic vs hydrophilic, or among individual statins, are of interest. When enough data are accumulated, further studies will be needed to determine the detailed effect of individual statins on new-onset of diabetes. Third, our study population included patients aged 30 to 85 years who attended our university hospital for various diseases, resulting in a higher prevalence of comorbidity in this study population than in the general population [42], potentially limiting the ability to generalize the results.

Fourth, there was a possibility that we had underestimated the follow-up period in the statin group, because of the time-lag between the first prescription and blood test of HbA1c or glucose level. However, checks of laboratory parameters, including parameters of lipid metabolism, renal function, hepatic function, and glucose metabolism, are routinely performed when starting statin therapy in our hospital. Therefore, the impact of the difference between the first prescription date and the blood test date on the findings of our study may be trivial. The findings of our study call for further studies with large samples, such as longitudinal cohort studies for a long-term period and randomized clinical trials, for confirmation.

**Conclusions**

In patients with various clinical backgrounds, in a real-world setting, those who received statin therapy had a higher risk of new-onset diabetes at 5 and 10 years than those who did not receive it. Effect modification of statins on new-onset diabetes was not found in patient populations defined according to various comorbid diseases or concomitant drugs.

**Table 3** Hazard ratio for new-onset diabetes, according to subgroup (Continued)

| Subgroup                  | No. of patients | Statin users | Non-users | Hazard ratio (95% CI) | P value for interaction |
|---------------------------|-----------------|--------------|-----------|-----------------------|-------------------------|
| H2 blocker use            |                 |              |           |                       |                         |
| Yes                       | 260             | 24 (18.6)    | 17 (13.0) | 1.57 (0.77–3.21)      | 0.8787                  |
| No                        | 740             | 54 (14.6)    | 31 (8.4)  | 1.68 (1.06–2.66)      |                         |
| NSAID use                 |                 |              |           |                       |                         |
| Yes                       | 171             | 26 (28.3)    | 10 (12.7) | 2.95 (1.36–6.39)      | 0.0786                  |
| No                        | 829             | 52 (12.8)    | 38 (9.0)  | 1.31 (0.83–2.06)      |                         |
| Non-thiazide diuretic use |                 |              |           |                       |                         |
| Yes                       | 135             | 14 (23.3)    | 9 (12.9)  | 1.38 (0.52–3.70)      | 0.7361                  |
| No                        | 870             | 64 (14.5)    | 39 (9.1)  | 1.66 (1.10–2.51)      |                         |
| Antiarrhythmic drug use   |                 |              |           |                       |                         |
| Yes                       | 69              | 6 (17.1)     | 7 (20.6)  | 0.67 (0.19–2.42)      | 0.1553                  |
| No                        | 931             | 72 (15.4)    | 41 (8.8)  | 1.78 (1.19–2.68)      |                         |

Hazard ratios and 95% confidence intervals (CI) were estimated using Cox hazards models adjusted for age, sex, and baseline levels of triglyceride and casual glucose. P values for heterogeneity were obtained by fitting interaction terms. Data of subgroups whose hazard ratios could not be calculated because of small samples are not shown.

Abbreviations: ARB, angiotensin type II receptor blocker; CCB, calcium channel blocker; H2 blocker, histamine2-receptor antagonist; NSAID, non-steroidal anti-inflammatory drug.
Abbreviations
ACE inhibitor: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin II receptor blocker; CCB: Calcium channel blocker; CDW: Clinical Data Warehouse; CI: Confidence interval; H2 blocker: Histamine2-receptor antagonist; HbA1c: Hemoglobin A1c; HMG-CoA reductase inhibitor; 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor; NSAID: Non-steroidal anti-inflammatory drug; NUSM: Nihon University School of Medicine; OGTT: Oral glucose tolerance test; PPI: Proton pump inhibitor

Authors’ contributions
KY participated in the conception and design of the study, data analysis, interpretation, and drafting the manuscript, and approved the final manuscript. YT participated in the conception and design of the study, data analysis, interpretation, and drafting the manuscript, provided critical revision of the manuscript, and approved the final manuscript. TN and SA participated in data interpretation, provided critical revision of the manuscript, and approved the final manuscript. All authors have read and approved the final article.

Funding
None.

Availability of data and materials
The datasets generated and analysed during the current study are not publicly available because approval was not obtained for the sharing of subject data from the Ethical Committee of NUSM. Data are however available from the corresponding author upon reasonable request and with permission of the Ethical Committee of NUSM.

Acknowledgments
This work was supported in part by the Health Sciences Research Institute, Inc., Yokohama, Japan and Convergence CT Japan KK, Tokyo, Japan.

Competing interests
The authors declare that they have no competing interest.

Author details
1 Division of Genomic Epidemiology and Clinical Trials, Clinical Trials Research Center, Nihon University School of Medicine, 30-1 Oyaguchi-Kami Machi, Itabashi-ku, Tokyo 173-8610, Japan. 2Division of Laboratory Medicine, Department of Pathology and Microbiology, Nihon University School of Medicine, 30-1 Oyaguchi-Kami Machi, Itabashi-ku, Tokyo 173-8610, Japan. 3Division of Pharmacology, Department of Biomedical Sciences, Nihon University School of Medicine, 30-1 Oyaguchi-Kami Machi, Itabashi-ku, Tokyo 173-8610, Japan.

Received: 18 March 2019 Accepted: 20 May 2019

References
1. Baigent C, Blackwell L, Emberson J, Holland LE, Keech C, Kralick J, Le waterproofing R, Levenon MJ, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 17,000 participants in 26 randomised trials. Lancet. 2010;376(9733):1670-81.
2. Yusuf S, Bosch J, Dagenais G, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, Lopez-Jaramillo P, Leiter LA, Dans A, et al. Cholesterol lowering in intermediate-risk persons with ischemic heart disease: summary of updated NICE guidance. BMJ. 2014;349:g4356.
3. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2013;129(25_Suppl_2):S1-S183.
4. Armitage J. The safety of statins in clinical practice. Lancet. 2007;370(9601):1781–90.
5. Shah RV, Goldfine AB. Statins and risk of new-onset diabetes mellitus. Circulation. 2012;126(16):e282–4.
6. Navease EP, Szczesniak A, Kolodziejczak M, Gorny B, Kubica J, Suryapranata H. Statins and risk of new-onset diabetes mellitus: is there a rationale for individualized statin therapy? Am J Cardiovasc Drugs. 2014;14(2):79–87.
7. Bang CN, Olin PM. Statin treatment, new-onset diabetes, and other adverse effects: a systematic review. Curr Cardiol Rep. 2014;16(3):461.
8. Beckett RD, Schepers SM, Gordon SK. Risk of new-onset diabetes associated with statin use. SAGE Open Med. 2015;3:2050312115605518.
9. Freeman DJ, Nattier J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the west of Scotland coronary prevention study. Circulation. 2001;103(3):357–62.
10. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.
11. Rajpathak SN, Kumbhani DJ, Crandall J, Bazzali N, Alderman M, Ridker PM, Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009;32(10):1924–9.
12. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freemantle N, Jukema JW, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–42.
13. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556–64.
14. Zaharan NL, Williams D, Bennett K. Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol. 2012;73(4):1118–24.
15. Davies N,ってしまいが、日本で新規の糖尿病が見られる。J Clin Pharmacol. 2012;73(4):1118–24.
16. Navease EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabizak T, Caputo S, Grzesk G, Kubica A, Swiatkiewicz I, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2012;111(18):1123–30.
17. Dormuth CR, Dillon KB, Paterson JM, James MT, Teare GF, Raymond CB, Rahme E, Tamim H, Lipscombe L. Higher potency statins and the risk of diabetes mellitus: a systematic review of observational studies of administrative databases. BMJ. 2015;348:g3244.
18. Cho Y, Choe E, Lee YH, Seo JW, Choi Y, Yun Y, Wang HJ, Ahn CW, Cha BS, Lee HC, et al. Risk of diabetes in patients treated with HMG-CoA reductase inhibitors. Metabolism. 2015;64(4):482–8.
19. Corraro G, Ibrahim B, Nicotra F, Soranna D, Merlino L, Catapano AL, Tragni E, Casula M, Gusà G, Mancia G, Statins and the risk of diabetes: evidence from a large population-based cohort study. Diabetes Care. 2014;37(8):2225–32.
20. Ma T, Chang MH, Tien L, Liou YS, Jong GP. The long-term effect of statins on the risk of new-onset diabetes mellitus in elderly Taiwanese patients with hypertension and dyslipidemia: a retrospective longitudinal cohort study. Drugs Aging. 2012;29(1):45–51.
21. Chen CW, Chen TC, Huang KY, Chou P, Chen PF, Lee CC. Differential impact of new-onset diabetes in different age groups: a population-based case-control study in women from an Asian country. Plos One. 2013;8(8):e71817.
22. Mansi I, Frei CR, Wang CP, Mortensen EM. Statins and new-onset diabetes mellitus and diabetic complications: a retrospective cohort study of US healthy adults. J Gen Intern Med. 2015;30(11):1599–610.
23. Lee J, Nish Y, Shin S, Lim HS, Park RW, Bae SK, Oh E, Kim GJ, Kim JH, Lee S. Impact of statins on risk of new-onset diabetes mellitus: a population-based cohort study using the Korean National Health Insurance claims database. Ther Clin Risk Manag. 2016;12:1533–43.
24. Yoon D, Sheen SS, Lee S, Choi YJ, Park RW, Lim HS. Statins and risk for new-onset diabetes mellitus: a real-world cohort study using a clinical research database. Medicine (Baltimore). 2016;95(46):e5429.
25. Takahashi Y, Nishida Y, Asai S. Utilization of health care databases for pharmacoepidemiology. Eur J Clin Pharmacol. 2012;68(2):123–9.
26. Kitamura N, Takahashi Y, Yamadate S, Asai S. Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records. Cardiovasc Diabetol. 2007;6:26.
27. Nishida Y, Takahashi Y, Nakayama T, Soma M, Asai S. Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study. Cardiovasc Diabetol. 2011;10:74.
28. Nishida Y, Takahashi Y, Nakayama T, Soma M, Kitamura N, Asai S. Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records. Cardiovasc Diabetol. 2010;9:38.
29. Nishida Y, Takahashi Y, Nakayama T, Soma M, Kitamura N, Asai S. Comparative effect of angiotensin II type I receptor blockers and calcium channel blockers on laboratory parameters in hypertensive patients with type 2 diabetes. Cardiovasc Diabetol. 2012;11:53.
30. Takahashi Y, Nishida Y, Nakayama T, Asai S. Adverse effect profile of trichlormethiazide: a retrospective observational study. Cardiovasc Diabetol. 2011;10:45.
31. Nishida Y, Takahashi Y, Susa N, Kanou N, Nakayama T, Asai S. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study. Cardiovasc Diabetol. 2013;12:159.
32. Takahashi Y, Nishida Y, Nakayama T, Asai S. Comparative effect of clopidogrel and aspirin versus aspirin alone on laboratory parameters: a retrospective, observational, cohort study. Cardiovasc Diabetol. 2013;12:87.
33. Susa N, Nishida Y, Yada Y, Nakayama T, Asai S, Takahashi Y. Comparative effect of fixed-dose combination tablets of candesartan cilexetil/amlopidine versus olmesartan medoxomil/azelnidipine on laboratory parameters in patients with hypertension: a retrospective cohort study. Clin Exp Hypertens. 2016;38(2):173–9.
34. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, Tominaga M, Oikawa S, Noda M, Kavamura T, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan diabetes society to National Glycohemoglobin Standardization Program values. J Diabetes Invest. 2012;3(1):39–40.
35. D’Agostino RB, Jr: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998, 17(19):2265–2281.
36. Cox E, Martin BC, Van Staa T, Garib E, Seibert U, Johnson ML. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for retrospective database analysis task force report—part II. Value Health. 2009;12(8):1053–61.
37. Austin P, Chiu M, Ko D, Goeree R, Tu J. Propensity score matching for estimating treatment effects. In: Analysis of Observational Health Care Data Using SAS. Edited by Faries D, Leon A, Haro J, Obenchain R. Cary: SAS Press; 2010: 51–84.
38. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia. 2006;49(8):1881–92.
39. Yada T, Nakata M, Shiraihi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca²⁺ signalling and insulin secretion due to blockade of L-type Ca²⁺ channels in rat islet beta-cells. Br J Pharmacol. 1999;126(5):1205–13.
40. Sleight P. Debate: subgroup analyses in clinical trials: fun to look at - but don’t believe them! Curr Control Trials Cardiovasc Med 2000, 1(1):25–27.
41. Goldfine AB. Statins: is it really time to reassess benefits and risks? N Engl J Med. 2012;366(19):1752–5.
42. Obba N, Setoguchi S, Sato T, Kubota K. Lipid-lowering drugs and risk of new-onset diabetes: a cohort study using Japanese healthcare data linked to clinical data for health screening. BMJ Open. 2017;7(6):e015935.